Effect of early use of AbobotulinumtoxinA after stroke on spasticity progression: Protocol for a randomised controlled pilot study in adult subjects with moderate to severe upper limb spasticity (ONTIME pilot)
Introduction: Approximately 15 million people suffer a stroke annually, up to 40% of which may develop spasticity, which can result in impaired limb function, pain and associated involuntary movements affecting motor control. Robust clinical data on spasticity progression, associated symptoms develo...
Main Authors: | Keng He Kong, Jovita Balcaitiene, Hugues Berard, Pascal Maisonobe, Khean Jin Goh, Witsanu Kumthornthip, Raymond L. Rosales |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2017-06-01
|
Series: | Contemporary Clinical Trials Communications |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2451865416300837 |
Similar Items
-
Early AbobotulinumtoxinA (Dysport®) in Post-Stroke Adult Upper Limb Spasticity: ONTIME Pilot Study
by: Raymond L Rosales, et al.
Published: (2018-06-01) -
AbobotulinumtoxinA (Dysport<sup>®</sup>), OnabotulinumtoxinA (Botox<sup>®</sup>), and IncobotulinumtoxinA (Xeomin<sup>®</sup>) Neurotoxin Content and Potential Implications for Duration of Response in Patients
by: Malgorzata Field, et al.
Published: (2018-12-01) -
Effectiveness of AbobotulinumtoxinA in Post-stroke Upper Limb Spasticity in Relation to Timing of Treatment
by: Jörg Wissel, et al.
Published: (2020-02-01) -
Cost-effectiveness analysis of abobotulinumtoxinA for the treatment of cervical dystonia in the United Kingdom
by: Muthukumar M, et al.
Published: (2017-04-01) -
Considerations on patient-related outcomes with the use of botulinum toxins: is switching products safe?
by: Fraint A, et al.
Published: (2016-02-01)